Recruiting
Phase 1

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Sponsor:

Artiva Biotherapeutics, Inc.

Code:

NCT06265220

Conditions

Lupus Nephritis - WHO Class III

Lupus Nephritis - WHO Class IV

Refractory Systemic Lupus Erythematosus

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AB-101

Cyclophosphamide

Fludarabine

Rituximab

Obinutuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information